Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance
Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance
This study is a post-marketing surveillance in Japan, and it is a local prospective and
 observational study of patients who have received Ciproxan intravenously as a first-line
 treatment for sepsis, secondary skin infections followed by superficial burn, post-surgical
 or post-traumatic, pneumonia, peritonitis, cholecystitis, cholangitis, anthrax. The objective
 of this study is to assess safety and efficacy of Ciproxan in daily clinical practice. A
 total of 3,000 patients are to be enrolled and assessed during the period of treatment with
 Ciproxan.
Inclusion Criteria:

 -  Patients who received Ciproxan as a first-line treatment were eligible for the study,
 among those with sepsis, secondary infection due to trauma, burn, or surgical wound,
 pneumonia, peritonitis, cholecystitis, cholangitis, and anthrax as the indications of
 this drug.

 Exclusion Criteria:

 -  Patients who are contraindicated based on the product label.